RenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration

Logo - Endovascular Today

July 20, 2023—RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Limited, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s transarterial microperfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors.

As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.

View the entire article on Endovascular Today

Previous Post
Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer
Next Post
RenovoRx, Imugene Partner to Deliver Oncolytic Virus Therapy